CY1113774T1 - ANTI-TNFa METHODS OF ADMINISTRATION - Google Patents
ANTI-TNFa METHODS OF ADMINISTRATIONInfo
- Publication number
- CY1113774T1 CY1113774T1 CY20131100199T CY131100199T CY1113774T1 CY 1113774 T1 CY1113774 T1 CY 1113774T1 CY 20131100199 T CY20131100199 T CY 20131100199T CY 131100199 T CY131100199 T CY 131100199T CY 1113774 T1 CY1113774 T1 CY 1113774T1
- Authority
- CY
- Cyprus
- Prior art keywords
- htnfa
- antibody
- methods
- sec
- less
- Prior art date
Links
Abstract
Αποκαλύπτονται μέθοδοι θεραπευτικής αγωγής διαταραχών, στις οποίες η δραστικότητα TNFa είναι επιβλαβής, μέσω δισεβδομαδιαίας, υποδόριας χορήγησης ανθρώπινων αντισωμάτων, κατά προτίμηση ανασυνδυασμένων ανθρώπινων αντισωμάτων, που δεσμεύονται ειδικά με ανθρώπινο παράγοντα νέκρωσης όγκων άλφα (hTNFa). Το αντίσωμα μπορεί να χορηγηθεί με ή χωρίς μεθοτρεξάτη. Αυτά τα αντισώματα έχουν υψηλή συγγένεια για hTNFa (π.χ., Kd= 10-8 Μ ή λιγότερο), αργό ρυθμό διάστασης για αποσύνδεση από hTNFa (π.χ, Koff= 10-3 sec-1 ή λιγότερο) και εξουδετερώνουν την δραστικότητα του hTNFa in vitro και in vivo. Αντίσωμα της εφεύρεσης μπορεί να είναι αντίσωμα πλήρους μήκους ή τμήμα αυτού που δεσμεύεται με αντιγόνο. Κιτ που περιέχουν φαρμακευτική σύνθεση και οδηγίες για χορήγηση δόσεων, και προγεμισμένες σύριγγες που περιέχουν φαρμακευτικές συνθέσεις περιλαμβάνονται επίσης στην εφεύρεση.Methods of treating disorders are disclosed, in which TNFα activity is harmful, through biweekly, subcutaneous administration of human antibodies, preferably recombinant human antibodies, which specifically bind to human tumor necrosis factor alpha (hTNFa). The antibody may be administered with or without methotrexate. These antibodies have a high affinity for hTNFa (e.g., Kd = 10-8 sec or less), slow dissociation rate for hTNFa (e.g., Koff = 10-3 sec-1 or less) and neutralize the activity of hTNFa in vitro and in vivo. An antibody of the invention may be a full length antibody or antigen-binding portion thereof. Kits containing pharmaceutical composition and dosage instructions, and pre-filled syringes containing pharmaceutical compositions are also included in the invention.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US29696101A | 2001-06-08 | 2001-06-08 | |
| EP02741849A EP1406656B1 (en) | 2001-06-08 | 2002-06-05 | Methods of administering anti-tnf-alpha antibodies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1113774T1 true CY1113774T1 (en) | 2016-07-27 |
Family
ID=57102337
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20131100199T CY1113774T1 (en) | 2001-06-08 | 2013-03-05 | ANTI-TNFa METHODS OF ADMINISTRATION |
Country Status (1)
| Country | Link |
|---|---|
| CY (1) | CY1113774T1 (en) |
-
2013
- 2013-03-05 CY CY20131100199T patent/CY1113774T1/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1120540T1 (en) | ANTI-TNFa METHODS OF ADMINISTRATION | |
| RU2421464C2 (en) | Human il-13 antibodies and their therapeutic application | |
| WO2004004633A3 (en) | Use of tnfalpha antibodies and another drug | |
| EA201992590A1 (en) | STABLE COMPOSITIONS OF ANTIBODIES TO THE RECIPE OF PROGRAMMABLE DAMAGE 1 (PD-1) AND WAYS OF THEIR APPLICATION | |
| TR200301846T2 (en) | Cripto-blocking Antibodies and their use. | |
| PE20021151A1 (en) | USE OF ANTI-TNF ANTIBODIES AS DRUGS IN THE TREATMENT OF SEPTIC DISORDERS IN ANEMIC RACIENTS | |
| ATE409181T1 (en) | PROTEOMIMETIC COMPOUNDS AND METHODS | |
| ATE535252T1 (en) | PEPTIDE CONJUGATE COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING ALZHEIMER'S DISEASE | |
| BR0008161A (en) | Use of a therapeutic composition for treating a tumor cell, therapeutic composition, and kit for treating a tumor cell | |
| EA200500782A1 (en) | TREATMENT OF HEMORRHAGIC SHOCK | |
| RU2015107889A (en) | COMPOSITION CONTAINING TWO ANTIBODIES CONSTRUCTED THAT THEY HAVE A REDUCED AND INCREASED EFFECTIVE FUNCTION | |
| MXPA05007823A (en) | Composition for and treatment of demyelinating diseases and paralysis by administration of remyelinating agents. | |
| ATE551060T1 (en) | COMPOSITIONS AND METHODS FOR TREATING NEOVASCULAR DISEASES | |
| ATE502053T1 (en) | RECOMBINANT TUMOR-SPECIFIC ANTIBODIES AND USE THEREOF | |
| AR040603A1 (en) | THE USE OF AN ANTI-TNFALFA HIGH AFFINITY NEUTRALIZING ANTIBODY IN THE MANUFACTURE OF A MEDICINAL PRODUCT AND ASSEMBLY OF ELEMENTS | |
| ATE420880T1 (en) | CONDENSED CYCLIC MODULATORS OF THE FUNCTION OF NUCLEAR HORMONE RECEPTORS | |
| PA8540501A1 (en) | PEG CONJUGATES OF HGF-NK4 | |
| DE60137146D1 (en) | FUSION CELLS AND CYTOKINE COMPOSITIONS FOR THE TREATMENT OF DISEASES | |
| EA200501821A1 (en) | PHARMACEUTICAL COMBINATION, CONTAINING MODAFINIL AND OTHER DRUG PREPARATION | |
| DE60222383D1 (en) | MEDICAMENT FOR THE ADMINISTRATION OF AMIFOSTIN AND RELATED ACTIVE SUBSTANCES | |
| DE69734574D1 (en) | RECOMBINANT ADENOVIRENVEKTOREN FOR GENE THERAPY OF HUMAN CANCER | |
| CY1113774T1 (en) | ANTI-TNFa METHODS OF ADMINISTRATION | |
| WO2001037873A3 (en) | Method and system to remove cytokine inhibitor in patients | |
| UY27323A1 (en) | METHODS TO MANAGE ANTI-TNFA ANTIBODIES | |
| Puca et al. | Comparative evaluation of bolus and fractionated administration modalities for two antibody-cytokine fusions in immunocompetent tumor-bearing mice |